Peptide compounds
Patent 5882645 Issued on March 16, 1999. Estimated Expiration Date: 
March 16, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 16, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3326682 P. falciparum CS-peptides as universal T-cell epitope Patent #: 5114713 InventorsAssigneeApplicationNo. 374560 filed on 03/13/1995US Classes:424/194.1, Conjugated via claimed linking group, bond, or coupling agent424/278.1, NONSPECIFIC IMMUNOEFFECTOR, PER SE (E.G., ADJUVANT, NONSPECIFIC IMMUNOSTI- MULATOR, NONSPECIFIC IMMUNOPOTENTIATOR, NONSPECIFIC IMMUNOSUPPRESSOR, NON- SPECIFIC IMMUNOMODULATOR, ETC.); OR NONSPECIFIC IMMUNOEFFECTOR, STABILIZER, EMULSIFIER, PRESERVATIVE, CARRIER, OR OTHER ADDITIVE FOR A COMPOSITION CON- TAINING AN IMMUNOGLOBULIN, AN ANTISERUM, AN ANTIBODY, OR FRAGMENT THEREOF, AN ANTIGEN, AN EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR530/334, Polymer supported synthesis, e.g., solid phase synthesis, Merrifield synthesis, etc.530/345Chemical aftertreatment, e.g., acylation, methylation, etc.ExaminersPrimary: Housel, James C.Assistant: Ashton, Rosemary Attorney, Agent or FirmForeign Patent References
International ClassesA61K 039/385A61K 038/00 Foreign Application Priority Data1992-07-24 GBAbstractSynthetic peptides are widely used to generate antibodies. To induce high antibody response, it is known to conjugate the peptide to a carrier protein (e.g. KLH, BSA) or to incorporate it into polylysine to form a multiple antigenic peptide. Anchors may be built in which are based on fatty acids. According to the invention there is provided a novel lipidic amino acid based anchor system which can maximally enhance the antigenicity of a short synthetic peptide. These novel compounds are entirely peptide-based and may therefore be produced automatically by some step wise peptide synthesis, preferably solid phase step wise peptide synthesis. According to the invention there is also provided such a process.Other References
Field of SearchConjugated via claimed linking group, bond, or coupling agentConjugate or complex NONSPECIFIC IMMUNOEFFECTOR, PER SE (E.G., ADJUVANT, NONSPECIFIC IMMUNOSTI- MULATOR, NONSPECIFIC IMMUNOPOTENTIATOR, NONSPECIFIC IMMUNOSUPPRESSOR, NON- SPECIFIC IMMUNOMODULATOR, ETC.); OR NONSPECIFIC IMMUNOEFFECTOR, STABILIZER, EMULSIFIER, PRESERVATIVE, CARRIER, OR OTHER ADDITIVE FOR A COMPOSITION CON- TAINING AN IMMUNOGLOBULIN, AN ANTISERUM, AN ANTIBODY, OR FRAGMENT THEREOF, AN ANTIGEN, AN EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR Chemical aftertreatment, e.g., acylation, methylation, etc. Polymer supported synthesis, e.g., solid phase synthesis, Merrifield synthesis, etc. |
| ||||||||||||||
